Literature DB >> 8357116

Levothyroxine therapy in patients with thyroid disease.

S J Mandel1, G A Brent, P R Larsen.   

Abstract

PURPOSE: To review the indications for and the proper monitoring of levothyroxine therapy in patients with thyroid disease. DATA SOURCES: Relevant English language articles published from 1966 to 1992 were identified through a MEDLINE search and manual searches of both identified articles and selected endocrinology texts. STUDY SELECTION: Studies, case reports, and review articles that contained data on the pathophysiologic aspects of relevant thyroid disorders and on the pharmacologic aspects of, indications for, and administration of levothyroxine therapy. DATA EXTRACTION: Data on the epidemiology, clinical manifestations, complications, and treatment of thyroid disorders were analyzed with respect to patient selection, methods, diagnostic criteria, and conclusions. These data were used to develop a rational approach to the management of such patients. RESULTS OF DATA SYNTHESIS: Levothyroxine is a reliable and commonly prescribed drug to treat thyroid disease, but excessive dosage may have adverse effects. In patients with hypothyroidism, levothyroxine is used as replacement therapy. For most patients, therapy can be initiated with a full replacement dosage (1.6 micrograms/kg body weight), which is usually 75 to 100 micrograms/day for women and 100 to 150 micrograms/d for men. The goal is to normalize the serum thyroid-stimulating hormone concentration. Levothyroxine is also used to suppress the serum thyroid-stimulating hormone concentration. A trial of thyroid-stimulating hormone suppressive therapy is indicated for most patients with benign solitary nonfunctioning thyroid nodules and for those with a history of thyroid cancer. Levothyroxine in non-thyroid-stimulating hormone-suppressive doses may also be indicated for patients with nontoxic multinodular goiter and for certain patients after lobectomy for benign thyroid nodules.
CONCLUSIONS: With proper patient monitoring, levothyroxine replacement therapy should be effective, inexpensive, and free of complications. Recommendations for thyroid-stimulating hormone suppression with levothyroxine are based on risk-benefit considerations of the biologic characteristics of the thyroid disorder and the individual patient.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8357116     DOI: 10.7326/0003-4819-119-6-199309150-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  50 in total

1.  Lack of TSH inhibition by exogenous L-T4 in a patient with follicular thyroid carcinoma.

Authors:  R Bruno; P Giannasio; P Bellitti; R Sinisi; F Arturi; D Russo; G Costante
Journal:  J Endocrinol Invest       Date:  2005 Jul-Aug       Impact factor: 4.256

2.  Levothyroxine replacement doses are affected by gender and weight, but not age.

Authors:  Madhuri Devdhar; Rebecca Drooger; Marieta Pehlivanova; Gurdeep Singh; Jacqueline Jonklaas
Journal:  Thyroid       Date:  2011-07-13       Impact factor: 6.568

3.  Interaction between levothyroxine and calcium carbonate.

Authors:  Elias E Mazokopakis; Triantafillos G Giannakopoulos; Ioannis K Starakis
Journal:  Can Fam Physician       Date:  2008-01       Impact factor: 3.275

4.  Pseudomalabsorption of Levothyroxine: A Challenge for the Endocrinologist in the Treatment of Hypothyroidism.

Authors:  Nancy Van Wilder; Bert Bravenboer; Sarah Herremans; Nathalie Vanderbruggen; Brigitte Velkeniers
Journal:  Eur Thyroid J       Date:  2016-11-24

5.  TSH Normalization in Bariatric Surgery Patients After the Switch from L-Thyroxine in Tablet to an Oral Liquid Formulation.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Stefania Camastra; Ugo Politti; Ilaria Ruffilli; Roberto Vita; Giuseppe Navarra; Salvatore Benvenga; Alessandro Antonelli
Journal:  Obes Surg       Date:  2017-01       Impact factor: 4.129

6.  Does an increase in the sensitivity of serum thyrotropin assays reduce diagnostic costs for thyroid disease in the community?

Authors:  M P Vanderpump; R H Neary; K Manning; R N Clayton
Journal:  J R Soc Med       Date:  1997-10       Impact factor: 5.344

7.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

8.  Provider and Patient Determinants of Generic Levothyroxine Prescribing: An Electronic Health Records-Based Study.

Authors:  Robert J Romanelli; Vani Nimbal; Sarah K Dutcher; Xia Pu; Jodi B Segal
Journal:  Ann Pharmacother       Date:  2017-04-20       Impact factor: 3.154

9.  Normal thyroxine and elevated thyrotropin concentrations: evolving hypothyroidism or persistent euthyroidism with reset thyrostat.

Authors:  U M Kabadi; R Cech
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

10.  A longitudinal assessment of bone loss in women with levothyroxine-suppressed benign thyroid disease and thyroid cancer.

Authors:  M T McDermott; J J Perloff; G S Kidd
Journal:  Calcif Tissue Int       Date:  1995-06       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.